Regulatory T cell therapies

The UCSF HICTF and GMP Facility manufactures the following regulatory T cell therapy products:

  • Ex vivo Expanded CD4+CD127lo/-CD25+ Alloantigen-Reactive Regulatory T Cells (arTregs) 
  • Ex vivo Expanded CD4+CD127lo/-CD25+ Polyclonal Regulatory T Cells [PDF of paper with expansion protocol]

    The facility has a limited capacity to partner with UCSF investigators to manufacture cellular therapy products.